NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
NeurAxis (NYSE American: NRXS) will release summarized financial results for its second quarter ended June 30, 2026, before market open on Tuesday, August 11, 2026.
Rhea-AI Summary
NeurAxis (NYSE American: NRXS) will release summarized financial results for its second quarter ended June 30, 2026, before market open on Tuesday, August 11, 2026. The company will host a conference call the same day at 9:00 a.m. ET to review the results, with live phone and webcast access plus a replay option.
Positive
- None.
Negative
- None.
Details
Market reaction after 2Q26 earnings report: NRXS -3.12% in the Jul 28 session
In the Jul 28 session, NRXS declined 3.12%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.1x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting period
- Q2 2026
- Period ended June 30, 2026
- Results date
- August 11, 2026
- Results scheduled before market open
- Conference call time
- 9:00 am ET
- August 11, 2026
Previous Earnings date Reports
-
Scheduled first-quarter results and conference call for May 12
-
Scheduled fourth-quarter and full-year results for March 19
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
neuromodulation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Tuesday, August 11, 2026, at 9:00am ET
Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060
Webcast: https://app.webinar.net/E5zrP9X7wLY
Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 8443629
Webcast: https://app.webinar.net/E5zrP9X7wLY
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.
For more information, please visit http://neuraxis.com.
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.